The final rule for the second year of the Medicare Access and CHIP Reauthorization Act (MACRA)’s Quality Payment Program (QPP) takes important steps toward acknowledging the challenges and concerns voiced by stakeholders regarding the ability of some clinicians to meet QPP reporting requirements.
On November 2, 2017, the Centers for Medicare & Medicaid Services (CMS) released its 2018 final rule, reflecting updates and changes to the Medicare Access and CHIP Reauthorization Act’s (MACRA) Quality Payment Program (QPP).
Escalating drug costs are compelling many states to develop and implement policy solutions to stem its rise. In fact, earlier this year, New York became the first state to place a cap on drug spending growth in its Medicaid program. Drug costs are also putting pressure on private health plans, which are looking to outcomes-based contracts as a possible solution, according to a survey by Avalere.
Industry executives from across the healthcare ecosystem, including payers, providers, pharmaceutical, health systems, technology, government agencies, device manufacturers and specialty pharmacy, gathered in Washington, D.C., for the 9th annual Inovalon Client Congress, October 1 – 3.
Many of us make important healthcare decisions with a surprising lack of rigor. Instead of conducting in-depth research one would expect with a potentially life-and-death decision, we often just ask those close to us for their advice or recommendations.
Why do we do this? Because when we start to peel the onion, we quickly experience a data avalanche of disparate and disconnected data points, a wide array of information that may or may not be relevant to our individual situation, but nothing resembling “the truth,” and often nothing valuable enough to help us make a decision. And we get overwhelmed. This isn’t unique to patient care decisions.